- Report
- November 2024
- 100 Pages
Global
From €5321EUR$5,950USD£4,615GBP
- Report
- October 2025
- 197 Pages
Global
From €3170EUR$3,545USD£2,750GBP
€3523EUR$3,939USD£3,055GBP
- Report
- October 2025
- 192 Pages
Global
From €3170EUR$3,545USD£2,750GBP
€3523EUR$3,939USD£3,055GBP
- Report
- August 2025
- 191 Pages
Global
From €3170EUR$3,545USD£2,750GBP
€3523EUR$3,939USD£3,055GBP
- Report
- August 2025
- 180 Pages
Global
From €3170EUR$3,545USD£2,750GBP
€3523EUR$3,939USD£3,055GBP
- Report
- August 2025
- 180 Pages
Global
From €3170EUR$3,545USD£2,750GBP
€3523EUR$3,939USD£3,055GBP
- Report
- October 2025
- 291 Pages
Global
From €5232EUR$5,850USD£4,538GBP
- Report
- September 2025
- 250 Pages
Global
From €4015EUR$4,490USD£3,483GBP
- Report
- April 2025
- 175 Pages
Global
From €4015EUR$4,490USD£3,483GBP
- Report
- April 2025
- 175 Pages
Global
From €4015EUR$4,490USD£3,483GBP
- Report
- April 2025
- 250 Pages
Global
From €4015EUR$4,490USD£3,483GBP
- Report
- April 2025
- 200 Pages
Global
From €7110EUR$7,950USD£6,167GBP
- Report
- November 2024
- 150 Pages
Global
From €3443EUR$3,850USD£2,986GBP
€4337EUR$4,850USD£3,762GBP
- Report
- September 2025
- 112 Pages
Global
From €3500EUR$4,192USD£3,142GBP
- Report
- October 2022
- 270 Pages
Global
From €2683EUR$3,000USD£2,327GBP
€3354EUR$3,750USD£2,909GBP
- Report
- September 2021
- 111 Pages
Global
From €4024EUR$4,500USD£3,491GBP
- Report
- May 2021
- 50 Pages
China
From €2325EUR$2,600USD£2,017GBP
- Report
- May 2024
- 200 Pages
Global
From €3711EUR$4,150USD£3,219GBP
- Report
- July 2024
- 231 Pages
Global
From €7110EUR$7,950USD£6,167GBP
- Report
- November 2023
- 30 Pages
Global
From €2906EUR$3,250USD£2,521GBP

Golimumab is a biologic drug used to treat immune disorders such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. It is a monoclonal antibody that works by blocking the action of tumor necrosis factor (TNF), a protein that plays a role in inflammation. Golimumab is administered as an intravenous infusion or subcutaneous injection.
Golimumab is one of several drugs used to treat immune disorders. Other drugs used to treat these conditions include biologics such as adalimumab, etanercept, and infliximab, as well as non-biologic drugs such as methotrexate and corticosteroids.
Golimumab is marketed by Janssen Biotech, Inc., a subsidiary of Johnson & Johnson. Other companies in the market include AbbVie, Amgen, and Pfizer. Show Less Read more